



Sheet 1 of 1

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: OC01128K	SERIAL NO.: 09/768,445
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>				APPLICANT: Houghton, et al.	
				FILING DATE: January 24, 2001	GROUP:

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE	
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION		
AL WO 97 07804 A					YES	NO	
AM							
AN							
AO							

OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>		
AP	Kano, Y., et al., "Effects of CPT-11 in Combination with Other Anti-Cancer Agents in Culture" February 2, 1992, International Journal of Cancer, Vol. 50, No. 4, pgs. 604-610	
AQ	Eder, JP et al., "Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo", 1998, Cancer Chemother. Pharmacol., Vol. 42, No. 4, pgs. 327-335	
AR	Plowman, J., et al., "Preclinical Antitumor Activity of Temozolomide in Mice: Efficacy Against Human Brain Tumor Xenografts and Synergism with 1,3-Bis (2-Chloroethyl)-1- Nitrosurea", 1994, Cancer Research, Vol. 54, No. 14, pgs. 3793-3799	
AS	Newlands, E.S., et al., "Temozolomide: A review of its Discovery, Chemical Properties, Pre-Clinical Development and Clinical Trials", 1997, Cancer Treatment Reviews, Vol. 23, No. 1, pgs. 35-61	
AT	Vikas J. Patel, et al., "Schedule-dependent Activity of Temozolomide plus CPT-11 against a Human Central Nervous System Tumor-derived Xenograft", 2000, Clinical Cancer Research, Vol. 6, pgs. 4154-4157	
AO	Peter J. Houghton, et al., "Antitumor Activity of Temozolomide Combined with Irinotecan is Partly Independent of O ⁶ -Methylguanine-DNA Methyltransferase and Mismatch Repair Phenotypes in Xenograft Models", 2000, Clinical Cancer Research, Vol. 6, pgs. 4110-4118	

EXAMINER	DATE CONSIDERED
	6-10-04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY OF PAPERS
ORIGINALLY FILED

Sheet 1 of 1

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.:
OC01128K

SERIAL NO.:
09/767,424

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

APPLICANT:
SARA L. ZAKNOEN

FILING DATE:
JANUARY 22, 2001

GROUP:

Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
am	AA 6,346,524 B1	02/02	RAGAB	A61K	31/33	
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES	NO
	AL						
	AM						
	AN						
	AO						
	AP						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AQ	
	AR	
	AS	
	AT	
	AU	
	AV	

EXAMINER

DATE CONSIDERED

am

6-10-04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.